Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.

导出 LinkOut

翻译打印收藏纠错

第一作者： Wolfgang F,Richter

第一单位： Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland. wolfgang.richter@roche.com.

作者： Wolfgang F,Richter ^[1] ; Hans-Peter,Grimm ^[2] ; Marie-Hélène,Gouy ^[2] ; Susi,Søgaard ^[3] ; Caroline,Kreuzer ^[2] ; Uwe,Wessels ^[4] ; Dragomir,Draganov ^[2] ; Chris,Muenzer ^[5] ; Tonio,Hoche ^[6]

作者单位： Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland. wolfgang.richter@roche.com. ^[1] Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland. ^[2] Charles River Laboratories Copenhagen A/S, Hestehavevej 36A, Ejby, 4623, Lille Skensved, Denmark. ^[3] Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, 82377, Penzberg, Germany. ^[4] Device Development, Pharmaceutical Technical Development Europe, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland. ^[5] Device Development & Commercialization, Technical Research & Development, Novartis AG, 4056, Basel, Switzerland. ^[6]

关键词 injection site differences monoclonal antibody subcutaneous administration translation to humans